1. Home
  2. ABIO

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Founded: N/A Country:
United States
United States
Employees: N/A City: WESTMINSTER
Market Cap: 47.3M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 1.5M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.42 EPS Growth: N/A
52 Week Low/High: $1.56 - $4.49 Next Earning Date: 04-25-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: